US2023348589A1PendingUtilityA1

Antibodies That Bind Human Cannabinoid 1 (CB1) Receptor

Assignee: BIRD ROCK BIO INCPriority: Mar 27, 2014Filed: Jan 27, 2023Published: Nov 2, 2023
Est. expiryMar 27, 2034(~7.7 yrs left)· nominal 20-yr term from priority
C07K 16/28A61K 47/6849C07K 2317/24C07K 2317/33C07K 2317/526C07K 2317/53C07K 2317/55C07K 2317/565C07K 2317/71C07K 2317/76C07K 2317/77C07K 2317/92C07K 2317/94A61K 2039/505A61K 39/395A61P 1/16A61P 13/12A61P 19/10A61P 25/04A61P 27/02A61P 27/06A61P 29/00A61P 3/00A61P 3/04A61P 35/00A61P 3/06A61P 43/00A61P 9/00A61P 9/10A61P 3/10C07K 2317/90C07K 2317/52C07K 2317/56C07K 2317/732C07K 2317/734
76
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to novel antibodies and fragments thereof that binds cannabinoid 1 (CB1) receptor. The antibodies and fragments thereof as disclosed herein include humanized antibodies that bind CB1 receptor. The invention also includes uses of the antibodies for treating a disease or disorder responsive to antagonism or agonism of the CB1 receptor.

Claims

exact text as granted — not AI-modified
1 . An isolated antibody or antigen binding fragment thereof that binds to cannabinoid 1 (CB1) receptor, wherein the antibody or fragment has a binding affinity Kd for CB1 receptor of about 1 μM or less.

Join the waitlist — get patent alerts

Track US2023348589A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.